Phorbol ester treatment down-regulates immunoglobulin RNA steady-state levels in B type chronic lymphocytic leukemia and non-Hodgkin's lymphoma cells

Leukemia. 1990 Sep;4(9):641-5.

Abstract

The human B-lymphoma cell lines BJAB and Daudi, as well as the human pre-B cell line KM3, were found to down-regulate steady-state immunoglobulin RNA levels 2- to 4-fold after stimulation with phorbol 12-myristate-13-acetate (PMA) for 24 hr. No down-regulation of the transcriptional rate of a kappa promoter could be observed in any of these cell lines upon transient expression transfection. The observed down-regulation of steady-state immunoglobulin RNA affected both the secretory and the membrane form of the mu transcript equally. When freshly isolated chronic lymphocytic leukemia (CLL) cells where tested for their response to PMA, three of four isolates responded by down-regulating their steady-state immunoglobulin RNA levels.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Down-Regulation / drug effects*
  • Gene Expression Regulation, Neoplastic / drug effects*
  • Genes, Immunoglobulin / drug effects
  • Humans
  • Immunoglobulin mu-Chains / genetics
  • Immunoglobulins / genetics*
  • Leukemia, Lymphocytic, Chronic, B-Cell / genetics*
  • Leukemia, Lymphocytic, Chronic, B-Cell / metabolism
  • Lymphoma, Non-Hodgkin / genetics*
  • Lymphoma, Non-Hodgkin / metabolism
  • Mice
  • RNA / metabolism*
  • RNA Splicing / drug effects
  • Tetradecanoylphorbol Acetate / pharmacology*
  • Transcription, Genetic / drug effects
  • Tumor Cells, Cultured / drug effects
  • Tumor Cells, Cultured / metabolism

Substances

  • Immunoglobulin mu-Chains
  • Immunoglobulins
  • RNA
  • Tetradecanoylphorbol Acetate